In the pancreatic cancer cells treated with GLS inhibitor CB-839, using uniformly 13C-labeled Gln to trace the itinerary of Gln-derived carbons in control versus CB-839-treated cells, it was discovered that it increased unlabeled Glu in the treated cells, indicating alternative pathways for Glu supply [73]. This evidence concerns the gene GLS and familial pancreatic carcinoma.